Thus, TF degradation mediated by E3 ubiquitin ligase is already being leveraged clinically for treatment of cancers reliant on IKZF1 and IKZF3, suggesting a powerful new therapeutic opportunity for potential development in the treatment of RMS. The gene discussed is TF; the disease is cancer.